ACC enzymes are considered to be potential drug targets for the treatment of liver cancer because knockdown of ACC1 in human HCC cells in vitro is sufficient to reduce cancer cell viability9, while loss of ACC activity in the liver is not associated with deleterious consequences to normal non-cancerous tissues17. Here, ACACA is linked to liver cancer.